# About CJC-1295 Ipamorelin Direct: An Independent Editorial Digest

> About CJC-1295 Ipamorelin Direct — an independent editorial project publishing cited, mechanism-first summaries of the CJC-1295 and ipamorelin research literature.

An independent editorial reading of the published literature — not a clinic, not a vendor, not a prescription.

## What this site is

CJC Ipa Direct is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295 Ipamorelin — the research combination of a long-acting GHRH analogue and a selective growth-hormone-releasing peptide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The "direct" in the name is editorial framing — a plain, mechanism-first reading of the record, with the pharmacology stated straight and the gaps left visible rather than filled. It describes the position this publisher takes relative to the literature. It is not a claim that the site offers any direct service, supply, consultation, or transaction.

## How we read the record

Our editorial standard is simple: every quantitative claim is tied to a numbered, peer-reviewed source, and claims about the fixed CJC-1295 + ipamorelin blend are attributed honestly to single-component or general-synergy data — never presented as if the blend itself had been clinically tested, because it has not. Where the data is precise, we report it precisely. Where it is missing — human pharmacokinetics for ipamorelin, any controlled trial of the combination — we say so plainly.

We describe research findings and clearly-labeled community reports. We do not give human dosing, treatment instructions, or prescriptions, and we report studied doses only as the amount administered to a particular species by a particular route. The full source list lives on the [CJC-1295 Ipamorelin references](/references) page.

## What we are not

We are not a healthcare provider, a compounding pharmacy, a supplement brand, or a peptide supplier. There is no clinical team, no dispensary, and no consultation behind this site — only an editorial reading of public science. Neither CJC-1295 nor ipamorelin is FDA-approved, and both are prohibited at all times in sport under the World Anti-Doping Code (Section S2); we state that on every page because it is part of the honest record.

If you are looking for medical guidance, this is not the place for it; that belongs to a qualified clinician who knows your history. What we offer is a careful, cited map of what the studies on CJC-1295 and ipamorelin actually measured — and an equally careful account of what they have not.

---

A mechanism-first reading of the CJC-1295 and ipamorelin record — two receptors, two timescales, every figure logged to its study and the untested fixed blend kept in plain view; no clinic behind the console and nothing here dosed, stacked, prescribed, or sold.